FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W115168017> ?p ?o ?g. }

• W115168017 endingPage "775" @default.
• W115168017 startingPage "765" @default.
• W115168017 abstract "Complexes of vanadyl(IV) with 4 monosaccharides and 5 disaccharides were tested in 2 osteoblast-like cell lines (MC3T3E1 and UMR106). Many complexes caused stimulation of UMR106 proliferation (120% basal) in the range of 2.5 to 25 µmol/L. In the nontransformed osteoblasts, some vanadyl–saccharide complexes stimulated the mitogenesis (115% basal) in the same range of concentration. The glucose and sucrose complexes were the most efficient inhibitory agents (65% and 88% of inhibition vs. basal, respectively) for tumoral cells at 100 µmol/L. The galactose and turanose complexes exerted a similar effect in the nontransformed osteoblasts. On the other hand, all the complexes promoted the phosphorylation of the extracellular regulated kinases (ERKs). All together, these results indicate that the stimulation of ERKs is not the only factor that plays a role in the proliferative effects of vanadium derivatives since some compounds were inhibitory proliferating agents. Cell differentiation was evaluated by alkaline phosphatase specific activity and collagen synthesis in UMR106 cells. All the complexes inhibited alkaline phosphatase activity, with galactose complex as the most effective compound (IC 50 = 43 µmol/L). The complex with the trehalose TreVO was the most effective agent to stimulate collagen synthesis (142% basal) and glucose consumption (132% basal). A cytosolic tyrosine protein kinase and the kinase-3 of glycogen synthase seem to be involved in the stimulation of glucose consumption by vanadium derivatives. In this series, only TreVO gathered the characteristics of a good insulin mimetic and osteogenic drug. In addition, this complex was a good promoting agent of nontransformed osteoblast proliferation, whereas it inhibited tumoral osteoblasts. GluVO, the complex with glucose, was also more toxic for tumoral than for nontransformed cells. These 2 vanadium derivatives are good potential antitumoral drugs. All the results suggest that the biological effects of vanadium compounds are a complex phenomenon influenced by the complexation, the dose, and the nature of the ligands and the cells." @default.
• W115168017 created "2016-06-24" @default.
• W115168017 creator A5026075102 @default.
• W115168017 creator A5050500778 @default.
• W115168017 creator A5050679388 @default.
• W115168017 creator A5078983280 @default.
• W115168017 date "2006-07-01" @default.
• W115168017 modified "2023-10-16" @default.
• W115168017 title "Vanadyl(IV) complexes with saccharides. Bioactivity in osteoblast-like cells in cultureThis paper is one of a selection of papers published in this Special issue, enititled Second Messengers and Phosphoproteins—12th International Conference." @default.
• W115168017 cites W1484619869 @default.
• W115168017 cites W1517681506 @default.
• W115168017 cites W1562951114 @default.
• W115168017 cites W1876341852 @default.
• W115168017 cites W1969364082 @default.
• W115168017 cites W1983435458 @default.
• W115168017 cites W1991800947 @default.
• W115168017 cites W1994597132 @default.
• W115168017 cites W1995277255 @default.
• W115168017 cites W2000529728 @default.
• W115168017 cites W2004986155 @default.
• W115168017 cites W2005115971 @default.
• W115168017 cites W2029491705 @default.
• W115168017 cites W2032108914 @default.
• W115168017 cites W2033361896 @default.
• W115168017 cites W2033931414 @default.
• W115168017 cites W2039707682 @default.
• W115168017 cites W2042158095 @default.
• W115168017 cites W2049735356 @default.
• W115168017 cites W2071548379 @default.
• W115168017 cites W2071660129 @default.
• W115168017 cites W2073180038 @default.
• W115168017 cites W2075104267 @default.
• W115168017 cites W2084360725 @default.
• W115168017 cites W2090265247 @default.
• W115168017 cites W2094976314 @default.
• W115168017 cites W2100837269 @default.
• W115168017 cites W2121795850 @default.
• W115168017 cites W2127213691 @default.
• W115168017 cites W213151801 @default.
• W115168017 cites W2136553577 @default.
• W115168017 cites W2162088346 @default.
• W115168017 cites W2167969877 @default.
• W115168017 cites W2226001858 @default.
• W115168017 cites W2340852340 @default.
• W115168017 cites W2466173225 @default.
• W115168017 cites W4230228942 @default.
• W115168017 cites W4230518742 @default.
• W115168017 cites W4250109249 @default.
• W115168017 cites W4293247451 @default.
• W115168017 doi "https://doi.org/10.1139/y06-021" @default.
• W115168017 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16998540" @default.
• W115168017 hasPublicationYear "2006" @default.
• W115168017 type Work @default.
• W115168017 sameAs 115168017 @default.
• W115168017 citedByCount "24" @default.
• W115168017 countsByYear W1151680172012 @default.
• W115168017 countsByYear W1151680172013 @default.
• W115168017 countsByYear W1151680172014 @default.
• W115168017 countsByYear W1151680172015 @default.
• W115168017 countsByYear W1151680172016 @default.
• W115168017 countsByYear W1151680172017 @default.
• W115168017 countsByYear W1151680172019 @default.
• W115168017 countsByYear W1151680172021 @default.
• W115168017 crossrefType "journal-article" @default.
• W115168017 hasAuthorship W115168017A5026075102 @default.
• W115168017 hasAuthorship W115168017A5050500778 @default.
• W115168017 hasAuthorship W115168017A5050679388 @default.
• W115168017 hasAuthorship W115168017A5078983280 @default.
• W115168017 hasConcept C126322002 @default.
• W115168017 hasConcept C134018914 @default.
• W115168017 hasConcept C160160445 @default.
• W115168017 hasConcept C181199279 @default.
• W115168017 hasConcept C184235292 @default.
• W115168017 hasConcept C185592680 @default.
• W115168017 hasConcept C202751555 @default.
• W115168017 hasConcept C24998067 @default.
• W115168017 hasConcept C2778173381 @default.
• W115168017 hasConcept C2778260815 @default.
• W115168017 hasConcept C28406088 @default.
• W115168017 hasConcept C55493867 @default.
• W115168017 hasConcept C71924100 @default.
• W115168017 hasConcept C86803240 @default.
• W115168017 hasConcept C95444343 @default.
• W115168017 hasConceptScore W115168017C126322002 @default.
• W115168017 hasConceptScore W115168017C134018914 @default.
• W115168017 hasConceptScore W115168017C160160445 @default.
• W115168017 hasConceptScore W115168017C181199279 @default.
• W115168017 hasConceptScore W115168017C184235292 @default.
• W115168017 hasConceptScore W115168017C185592680 @default.
• W115168017 hasConceptScore W115168017C202751555 @default.
• W115168017 hasConceptScore W115168017C24998067 @default.
• W115168017 hasConceptScore W115168017C2778173381 @default.
• W115168017 hasConceptScore W115168017C2778260815 @default.
• W115168017 hasConceptScore W115168017C28406088 @default.
• W115168017 hasConceptScore W115168017C55493867 @default.
• W115168017 hasConceptScore W115168017C71924100 @default.
• W115168017 hasConceptScore W115168017C86803240 @default.
• W115168017 hasConceptScore W115168017C95444343 @default.

• next